Q: What is Talvey used for?

Talvey is used to treat multiple myeloma .

Q: How does Talvey work?

Mechanism of Action Talvey is a type of immunotherapy known as a bispecific T-cell engager. It is designed to act as a bridge between the body's immune system and cancer cells to help the body fight multiple myeloma. The medication works by targeting two specific proteins at the same time: GPRC5D: A protein found on the surface of multiple myeloma cells. CD3: A protein found on the surface of T-cells, which are white blood cells responsible for fighting disease and infection. By attaching to both of these proteins simultaneously, Talvey brings the T-cells into close physical contact with the myeloma cells. This proximity allows the T-cells to recognize the cancer cells and release substances that destroy them. This process helps the immune system more effectively find and eliminate cancer cells that might otherwise hide from the body's natural defenses.

Q: What are the active ingredients in Talvey?

The active ingredient in Talvey is talquetamab .

Q: What are the side effects of Talvey?

Common side effects of Talvey may include: fever fatigue nausea and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Talvey?

Talvey belongs to the PARP inhibitor drug class.

Q: What is the dosage of Talvey and how do I take it?

Administration Method Talvey is given as a subcutaneous injection, which means it is injected into the layer of fat just under the skin. Common injection sites include the stomach area or the thigh. A healthcare provider will perform the injection in a clinical setting, such as a hospital or infusion center. Dosing Schedule Treatment with Talvey usually follows a specific pattern known as a step-up dosing schedule. This process involves receiving smaller doses a few days apart at the start of treatment. This approach helps the body adjust to the medication before moving to the full treatment dose. Once the initial step-up phase is complete, the medication is typically administered on a regular maintenance schedule. Depending on the treatment plan determined by a doctor, injections may be given once every week or once every two weeks. Monitoring During Treatment Because of the potential for certain reactions, patients are often required to stay at the healthcare facility for monitoring for a period of time after receiving the first few doses. This allows medical staff to watch for and manage any immediate side effects. Missed Doses It is important to receive every scheduled dose of Talvey. If an appointment is missed, patients should contact their healthcare provider as soon as possible to reschedule. The provider will determine the best way to get back on schedule, which may involve repeating certain steps of the dosing process if too much time has passed between injections.

Q: Is Talvey safe during pregnancy and breastfeeding?

Pregnancy Talvey can cause harm to a fetus if used during pregnancy. Healthcare providers typically perform a pregnancy test before starting treatment to ensure a patient is not pregnant. Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 3 months after the final dose. If a patient becomes pregnant while using this medication, they should notify their healthcare provider immediately. Breastfeeding It is not known if Talvey passes into human breast milk. Due to the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 3 months after the last dose. Patients should discuss their options for infant feeding with their healthcare team before starting this medication.

Q: What is the FDA approval status of Talvey?

FDA Approval Status Talvey (talquetamab-tgvs) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2023. It is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Boxed Warning The FDA requires a Boxed Warning for Talvey because it can cause serious or life-threatening side effects, including: Cytokine Release Syndrome (CRS): A condition where the immune system reacts too strongly to the medication. Neurologic Toxicity: This includes Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can cause symptoms like confusion, disorientation, or loss of consciousness. REMS Program Because of the risks of CRS and neurologic toxicity, Talvey is only available through a restricted program called the Tecvayli-Talvey Risk Evaluation and Mitigation Strategy (REMS). Healthcare providers who prescribe Talvey and the facilities that dispense it must be specially certified. Patients must also be enrolled in the program and receive a Patient Wallet Card to carry at all times. Regulatory Monitoring The FDA continues to evaluate the safety of Talvey through the FDA Adverse Event Reporting System (FAERS). This system tracks potential signals of serious risks or new safety information identified after the drug has been approved for public use.

Question 1

What is Talvey?

Accepted Answer

Talvey is a bispecific T-cell engager that helps the immune system target and eliminate cancer cells. It works by binding to two different proteins at the same time: one found on the surface of the cancer cells and another found on T cells, which are a type of white blood cell.

By linking these two cells together, the medication allows the immune system to directly attack the cancer. This action helps the body's natural defenses identify and destroy cells that might otherwise go undetected.

Question 2

What is Talvey used for?

Accepted Answer

Talvey is used to treat multiple myeloma.

Question 3

How does Talvey work?

Accepted Answer

Mechanism of Action

Talvey is a type of immunotherapy known as a bispecific T-cell engager. It is designed to act as a bridge between the body's immune system and cancer cells to help the body fight multiple myeloma.

The medication works by targeting two specific proteins at the same time:

GPRC5D: A protein found on the surface of multiple myeloma cells.
CD3: A protein found on the surface of T-cells, which are white blood cells responsible for fighting disease and infection.

By attaching to both of these proteins simultaneously, Talvey brings the T-cells into close physical contact with the myeloma cells. This proximity allows the T-cells to recognize the cancer cells and release substances that destroy them. This process helps the immune system more effectively find and eliminate cancer cells that might otherwise hide from the body's natural defenses.

Question 4

What are the active ingredients in Talvey?

Accepted Answer

The active ingredient in Talvey is talquetamab.

Question 5

What are the side effects of Talvey?

Accepted Answer

Common side effects of Talvey may include:

fever
fatigue
nausea
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Talvey?

Accepted Answer

Talvey belongs to the PARP inhibitor drug class.

Question 7

What is the dosage of Talvey and how do I take it?

Accepted Answer

Administration Method

Talvey is given as a subcutaneous injection, which means it is injected into the layer of fat just under the skin. Common injection sites include the stomach area or the thigh. A healthcare provider will perform the injection in a clinical setting, such as a hospital or infusion center.

Dosing Schedule

Treatment with Talvey usually follows a specific pattern known as a step-up dosing schedule. This process involves receiving smaller doses a few days apart at the start of treatment. This approach helps the body adjust to the medication before moving to the full treatment dose.

Once the initial step-up phase is complete, the medication is typically administered on a regular maintenance schedule. Depending on the treatment plan determined by a doctor, injections may be given once every week or once every two weeks.

Monitoring During Treatment

Because of the potential for certain reactions, patients are often required to stay at the healthcare facility for monitoring for a period of time after receiving the first few doses. This allows medical staff to watch for and manage any immediate side effects.

Missed Doses

It is important to receive every scheduled dose of Talvey. If an appointment is missed, patients should contact their healthcare provider as soon as possible to reschedule. The provider will determine the best way to get back on schedule, which may involve repeating certain steps of the dosing process if too much time has passed between injections.

Question 8

Is Talvey safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Talvey can cause harm to a fetus if used during pregnancy. Healthcare providers typically perform a pregnancy test before starting treatment to ensure a patient is not pregnant.

Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 3 months after the final dose. If a patient becomes pregnant while using this medication, they should notify their healthcare provider immediately.

Breastfeeding

It is not known if Talvey passes into human breast milk. Due to the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 3 months after the last dose.

Patients should discuss their options for infant feeding with their healthcare team before starting this medication.

Question 9

What forms and strengths does Talvey come in?

Accepted Answer

Talvey is available as a liquid solution for injection. It is administered as a subcutaneous injection, which is an injection given into the tissue just under the skin.

This medication is supplied in vials for use by a healthcare professional.

Question 10

What is the FDA approval status of Talvey?

Accepted Answer

FDA Approval Status

Talvey (talquetamab-tgvs) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2023. It is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Boxed Warning

The FDA requires a Boxed Warning for Talvey because it can cause serious or life-threatening side effects, including:

Cytokine Release Syndrome (CRS): A condition where the immune system reacts too strongly to the medication.
Neurologic Toxicity: This includes Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can cause symptoms like confusion, disorientation, or loss of consciousness.

REMS Program

Because of the risks of CRS and neurologic toxicity, Talvey is only available through a restricted program called the Tecvayli-Talvey Risk Evaluation and Mitigation Strategy (REMS). Healthcare providers who prescribe Talvey and the facilities that dispense it must be specially certified. Patients must also be enrolled in the program and receive a Patient Wallet Card to carry at all times.

Regulatory Monitoring

The FDA continues to evaluate the safety of Talvey through the FDA Adverse Event Reporting System (FAERS). This system tracks potential signals of serious risks or new safety information identified after the drug has been approved for public use.

Question 11

What should I know about Talvey and withdrawal?

Accepted Answer

Based on current clinical data and prescribing information, there are no reported withdrawal symptoms associated with stopping Talvey. This medication is a bispecific antibody used for immunotherapy and does not cause physical dependence or the types of withdrawal effects seen with medications that affect the central nervous system, such as opioids or sedatives.

Although withdrawal is not a concern, you should only stop using Talvey under the direction of your healthcare provider. Discontinuing treatment may allow the underlying multiple myeloma to progress. Your doctor may decide to delay or permanently stop treatment if you experience certain serious side effects, including:

Cytokine release syndrome (CRS)
Neurologic problems (ICANS)
Severe skin reactions
Serious infections
Liver toxicity

If your treatment is discontinued, your healthcare team will continue to monitor you for any changes in your condition or lingering side effects from the medication.

Talvey

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Talvey

Hospitals.net Disclosure